Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
INFI's Cash-to-Debt is ranked higher than
96% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. INFI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INFI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28  Med: 1312.07 Max: 13254
Current: No Debt
0.28
13254
Equity-to-Asset 0.91
INFI's Equity-to-Asset is ranked lower than
99.99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INFI: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
INFI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.03  Med: 0.65 Max: 0.94
Current: 0.91
-0.03
0.94
Piotroski F-Score: 4
Altman Z-Score: -0.04
Beneish M-Score: 12.85
WACC vs ROIC
20.80%
-499.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -52.24
INFI's Operating Margin % is ranked lower than
69% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. INFI: -52.24 )
Ranked among companies with meaningful Operating Margin % only.
INFI' s Operating Margin % Range Over the Past 10 Years
Min: -764.34  Med: -91.69 Max: 22.94
Current: -52.24
-764.34
22.94
Net Margin % -46.95
INFI's Net Margin % is ranked lower than
69% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. INFI: -46.95 )
Ranked among companies with meaningful Net Margin % only.
INFI' s Net Margin % Range Over the Past 10 Years
Min: -697.17  Med: -68.67 Max: 28.35
Current: -46.95
-697.17
28.35
ROE % -20.51
INFI's ROE % is ranked lower than
60% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. INFI: -20.51 )
Ranked among companies with meaningful ROE % only.
INFI' s ROE % Range Over the Past 10 Years
Min: -123.36  Med: -41.42 Max: 27.59
Current: -20.51
-123.36
27.59
ROA % -17.76
INFI's ROA % is ranked lower than
61% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. INFI: -17.76 )
Ranked among companies with meaningful ROA % only.
INFI' s ROA % Range Over the Past 10 Years
Min: -45.22  Med: -27.81 Max: 16.29
Current: -17.76
-45.22
16.29
ROC (Joel Greenblatt) % -259.70
INFI's ROC (Joel Greenblatt) % is ranked lower than
52% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. INFI: -259.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INFI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3156.78  Med: -543.5 Max: 418.86
Current: -259.7
-3156.78
418.86
3-Year Revenue Growth Rate -67.30
INFI's 3-Year Revenue Growth Rate is ranked lower than
88% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INFI: -67.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INFI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.2 Max: 154.4
Current: -67.3
0
154.4
3-Year EBITDA Growth Rate -87.30
INFI's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INFI: -87.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INFI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17.5 Max: 55.4
Current: -87.3
0
55.4
3-Year EPS without NRI Growth Rate -32.10
INFI's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. INFI: -32.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INFI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.95 Max: 64
Current: -32.1
0
64
GuruFocus has detected 2 Warning Signs with Infinity Pharmaceuticals Inc INFI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INFI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

INFI Guru Trades in Q3 2017

Jim Simons 1,610,000 sh (+37.62%)
» More
Q4 2017

INFI Guru Trades in Q4 2017

Charles Brandes 27,500 sh (New)
Jim Simons 717,900 sh (-55.41%)
» More
Q1 2018

INFI Guru Trades in Q1 2018

Charles Brandes Sold Out
Jim Simons 567,500 sh (-20.95%)
» More
Q2 2018

INFI Guru Trades in Q2 2018

First Eagle Investment 500,000 sh (New)
Jim Simons 542,700 sh (-4.37%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OTIC, XTAE:CBI, NAS:BDSI, OTCPK:HPPI, NAS:PRQR, ROCO:4130, NAS:TRVN, OTCPK:CYDY, NAS:AXON, NAS:CKPT, LSE:DDDD, TPE:1786, NAS:CFRX, TSE:2370, NAS:OMED, NAS:CERC, NAS:BTAI, OTCPK:DGJI, TSE:4572, WAR:BIO » details
Traded in other countries:I3F.Germany,
Headquarter Location:USA
Infinity Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. It is focused on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate.

Infinity is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products, and those under development, include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments.

Top Ranked Articles about Infinity Pharmaceuticals Inc

Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Infinity Announces IPI-549 Late-Breaking Presentation at SITC 33rd Annual Meeting
Infinity Announces the Date of Its Third Quarter 2018 Financial Results Conference Call and Webcast
Report: Exploring Fundamental Drivers Behind Infinity Pharmaceuticals, AxoGen, MUELLER WATER PRODUCTS, MYR Group, RealNetworks, and Odonate Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
Infinity To Present At BIO Investor Forum
Infinity Pharmaceuticals Earns $22 Million Payment From Verastem Oncology For FDA Approval Of COPIKTRA™ (duvelisib) And Updates 2018 Financial Guidance
/C O R R E C T I O N -- Infinity Pharmaceuticals, Inc./
Infinity To Present At Cantor Fitzgerald Global Healthcare Conference

Ratios

vs
industry
vs
history
PB Ratio 1.28
INFI's PB Ratio is ranked higher than
66% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INFI: 1.28 )
Ranked among companies with meaningful PB Ratio only.
INFI' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 2.57 Max: 51.43
Current: 1.28
0.45
51.43
PS Ratio 3.54
INFI's PS Ratio is ranked lower than
59% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: 3.54 )
Ranked among companies with meaningful PS Ratio only.
INFI' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 4.31 Max: 60.95
Current: 3.54
0.55
60.95
EV-to-EBIT -3.15
INFI's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. INFI: -3.15 )
Ranked among companies with meaningful EV-to-EBIT only.
INFI' s EV-to-EBIT Range Over the Past 10 Years
Min: -161.2  Med: -2 Max: 94.2
Current: -3.15
-161.2
94.2
EV-to-EBITDA -3.21
INFI's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. INFI: -3.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
INFI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -862.7  Med: -2.1 Max: 26.1
Current: -3.21
-862.7
26.1
EV-to-Revenue 1.59
INFI's EV-to-Revenue is ranked higher than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. INFI: 1.59 )
Ranked among companies with meaningful EV-to-Revenue only.
INFI' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.7  Med: 2 Max: 93.5
Current: 1.59
-1.7
93.5
Current Ratio 10.67
INFI's Current Ratio is ranked higher than
73% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. INFI: 10.67 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 8.32 Max: 17.81
Current: 10.67
0.64
17.81
Quick Ratio 10.67
INFI's Quick Ratio is ranked higher than
74% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. INFI: 10.67 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 8.3 Max: 17.81
Current: 10.67
0.41
17.81
Days Sales Outstanding 365.00
INFI's Days Sales Outstanding is ranked lower than
99.99% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. INFI: 365.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.97  Med: 18.21 Max: 365
Current: 365
3.97
365

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.30
INFI's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. INFI: -1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INFI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.7  Med: -10.45 Max: -0.8
Current: -1.3
-178.7
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.14
INFI's Price-to-Net-Cash is ranked higher than
81% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. INFI: 2.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INFI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.85  Med: 2.67 Max: 38.43
Current: 2.14
0.85
38.43
Price-to-Net-Current-Asset-Value 1.30
INFI's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. INFI: 1.30 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INFI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.74  Med: 2.44 Max: 398.67
Current: 1.3
0.74
398.67
Price-to-Tangible-Book 1.29
INFI's Price-to-Tangible-Book is ranked higher than
73% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. INFI: 1.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INFI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 46.18
Current: 1.29
0.55
46.18
Price-to-Median-PS-Value 0.82
INFI's Price-to-Median-PS-Value is ranked lower than
92% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. INFI: 0.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INFI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.82 Max: 13.89
Current: 0.82
0.13
13.89
Earnings Yield (Greenblatt) % -31.81
INFI's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. INFI: -31.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INFI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4415.2  Med: -29.3 Max: 8304.4
Current: -31.81
-4415.2
8304.4

More Statistics

Revenue (TTM) (Mil) $22.00
EPS (TTM) $ -0.22
Beta3.13
Volatility52.72%
52-Week Range $1.26 - 2.92
Shares Outstanding (Mil)56.87

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.74 -0.76 -0.91 -0.67
EPS without NRI ($) -0.74 -0.76 -0.91 -0.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

» More Articles for NAS:INFI

Headlines

Articles On GuruFocus.com

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}